106 related articles for article (PubMed ID: 20039300)
1. In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: maintained tolerance to normal cells even in the presence of IL-2.
Vahlne G; Lindholm K; Meier A; Wickström S; Lakshmikanth T; Brennan F; Wilken M; Nielsen R; Romagné F; Wagtmann NR; Kärre K; Johansson MH
Eur J Immunol; 2010 Mar; 40(3):813-23. PubMed ID: 20039300
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo.
Koh CY; Blazar BR; George T; Welniak LA; Capitini CM; Raziuddin A; Murphy WJ; Bennett M
Blood; 2001 May; 97(10):3132-7. PubMed ID: 11342440
[TBL] [Abstract][Full Text] [Related]
3. Role of interaction between Ly49 inhibitory receptors and cognate MHC I molecules in IL2-induced development of NK cells in murine bone marrow cell cultures.
Das A; Saxena RK
Immunol Lett; 2004 Jul; 94(3):209-14. PubMed ID: 15275968
[TBL] [Abstract][Full Text] [Related]
4. Major histocompatibility complex genes determine natural killer cell tolerance.
Dorfman JR; Raulet DH
Eur J Immunol; 1996 Jan; 26(1):151-5. PubMed ID: 8566058
[TBL] [Abstract][Full Text] [Related]
5. Tolerance and alloreactivity of the Ly49D subset of murine NK cells.
George TC; Ortaldo JR; Lemieux S; Kumar V; Bennett M
J Immunol; 1999 Aug; 163(4):1859-67. PubMed ID: 10438920
[TBL] [Abstract][Full Text] [Related]
6. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
7. Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2.
Berinstein N; Starnes CO; Levy R
J Immunol; 1988 Apr; 140(8):2839-45. PubMed ID: 3258621
[TBL] [Abstract][Full Text] [Related]
8. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
Fan Z; Masui H; Altas I; Mendelsohn J
Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
[TBL] [Abstract][Full Text] [Related]
9. NK inhibitory-receptor blockade for purging of leukemia: effects on hematopoietic reconstitution.
Koh CY; Raziuddin A; Welniak LA; Blazar BR; Bennett M; Murphy WJ
Biol Blood Marrow Transplant; 2002; 8(1):17-25. PubMed ID: 11846352
[TBL] [Abstract][Full Text] [Related]
10. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T helper dysfunction.
Hirsch R; Archibald J; Gress RE
J Immunol; 1991 Oct; 147(7):2088-93. PubMed ID: 1833451
[TBL] [Abstract][Full Text] [Related]
11. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of Ly49s-positive or -negative natural killer cells is inhibited by anti-H-2b monoclonal antibodies acting at the level of bone marrow progenitors from B6 mice.
Delfino DV; Salcedo M; Marco BD; Ayroldi E; Nocentini G; Bruscoli S; Brunetti L; Ljunggren HG; Riccardi C
Cell Growth Differ; 2001 Jan; 12(1):51-60. PubMed ID: 11205745
[TBL] [Abstract][Full Text] [Related]
13. In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell-depleted marrow for the promotion of engraftment.
Blazar BR; Hirsch R; Gress RE; Carroll SF; Vallera DA
J Immunol; 1991 Sep; 147(5):1492-503. PubMed ID: 1831826
[TBL] [Abstract][Full Text] [Related]
14. Rat interleukin-2-activated natural killer (A-NK) cell-mediated lysis is determined by the presence of CD18 on A-NK cells and the absence of major histocompatibility complex class I on target cells.
Smits KM; Kuppen PJ; Eggermont AM; Tamatani T; Miyasaka M; Fleuren GJ
Eur J Immunol; 1994 Jan; 24(1):171-5. PubMed ID: 7912675
[TBL] [Abstract][Full Text] [Related]
15. Altered donor and recipient Ly49+ NK cell subsets in allogeneic H-2d --> H-2b and H-2b --> H-2d bone marrow chimeras.
Korten S; Wilk E; Gessner JE; Meyer D; Schmidt RE
J Immunol; 1999 Dec; 163(11):5896-905. PubMed ID: 10570275
[TBL] [Abstract][Full Text] [Related]
16. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
Lin CY; Chuang TF; Liao KW; Huang YJ; Pai CC; Chu RM
Cancer Lett; 2008 Dec; 272(2):285-95. PubMed ID: 18760876
[TBL] [Abstract][Full Text] [Related]
17. Positive recognition of MHC class I molecules by the Ly49D receptor of murine NK cells.
George TC; Mason LH; Ortaldo JR; Kumar V; Bennett M
J Immunol; 1999 Feb; 162(4):2035-43. PubMed ID: 9973475
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor.
Mingari MC; Vitale C; Cantoni C; Bellomo R; Ponte M; Schiavetti F; Bertone S; Moretta A; Moretta L
Eur J Immunol; 1997 Jun; 27(6):1374-80. PubMed ID: 9209487
[TBL] [Abstract][Full Text] [Related]
19. Two distinct porcine natural killer lytic trigger molecules as PNK-E/G7 molecular complex.
Wierda WG; Johnson BD; Dato ME; Kim YB
Cell Immunol; 1993 Feb; 146(2):270-83. PubMed ID: 8174170
[TBL] [Abstract][Full Text] [Related]
20. Self-tolerance of human natural killer cells lacking self-HLA-specific inhibitory receptors.
Hasenkamp J; Borgerding A; Uhrberg M; Falk C; Chapuy B; Wulf G; Jung W; Trümper L; Glass B
Scand J Immunol; 2008 Mar; 67(3):218-29. PubMed ID: 18226015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
